WELCOME to: 'Stu's Views and MS News' an informational archive provided by MS Views and News

· Key-Note: This blog provides education, information and resources to benefit those affected by Multiple Sclerosis.

· Opt-In at our website (MS Views and News) to receive our globally transmitted Multiple Sclerosis e-newsletter, currently being received in more than (90) Countries.

· Our live MS educational seminars average 67 people per educational program. SINCE our first program in February 2010, we have hosted more than 130 educational programs.

· Visit our Multiple Sclerosis Learning channel on YouTube archived by topic here: www.youtube.com/msviewsandnews

Be Empowered with Beneficial MS Information - ---Visit MS Views and News.org

joomla ecommerce template

View all the resources found on the left side of this blog. Use our 'search by topic' tool, when wanting to find specificinformation.

==================================================================

Wednesday, November 14, 2012

Nuron closing in on new treatment for relapsing MS


Tuesday, November 13, 2012
Nuron Biotech Inc. said Tuesday it has completed enrollment of 500 patients for a pivotal phase-III study evaluating the safety and effectiveness of the company’s experimental multiple sclerosis treatment.
Phase-III studies are typically the last hurdle a drug developer must clear before seeking approval for a new drug candidate.
Nuron, an Exton, Pa., specialty biologics and vaccines company, is developing NU100 to treat relapsing remitting multiple sclerosis.
Shankar Musunuri, the company’s founder and CEO, said it expects to complete the study in late 2013.
The company hopes to use the results of the study to support the filing of a European marketing authorization application.
Source: BizJournals

..


If you would like, you can comment to our blog posts
 LIKE this Blog by clicking the LIKE button - top left
 REMAIN up to date with MS News and Education
Visit: www.msviewsandnews.org  to register
.

No comments: